PillRx only · Spray, Metered · Nasal
Dihydroergotamine Mesylate Nasal
Dihydroergotamine Mesylate
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$40.817
Latest avg · Jul 22, 2026
+26%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
207
Rx · 2026 Q1
1.7K
Units dispensed
-52%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Cipla USA Inc. | unknown | 2 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.